EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection

Stuart Byrne, Takamichi Baba iD, Nao Kawaguchi iD, Atsuko Yamamoto iD, Yoshiyuki Nakano, Caroline Dorrepaal, Brandon Londt, Alex Mann iD, Nikolay Veselinski, Takeki Uehara iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag367 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Stuart Byrne und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Respiratory Syncytial Virus, Human. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model.

Methods

Healthy adults aged 18–55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2–12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set. Safety was assessed in all randomized participants. Dose-response was evaluated across a wide dose range (1–300 mg).

Results

Of 114 randomized participants, 60 comprised the ITT-I set. Covariate-adjusted mean viral load area under the curve (VL-AUC) was significantly lower in the 30- and 300-mg groups by qRT-PCR (64.87% and 88.94% reductions, respectively, both P < .05) and by viral culture assay (72.32% and 86.17% reductions, respectively, both P < .05). Total symptom score AUC was 78.15% lower in the 300-mg group (P < .05). S-337395 was well-tolerated without any safety concerns.

Conclusions

S-337395 significantly reduced viral load, viral titer, and symptoms, and was well-tolerated in this human challenge study. Clinical Trial Registration: ISRCTN24865912.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsAntiviral AgentsRespiratory Syncytial Virus, HumanHumansAdultFemaleMiddle AgedMaleDouble-Blind MethodYoung AdultHuman Challenge Trials as TopicAdolescentViral LoadDose-Response Relationship, Drug

Stichwörter der Autor:innen

L-protein inhibitorS-337395antiviralhuman challengerespiratory syncytial virus

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
  • Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Medical Science Department, Shionogi B.V., London, England, United Kingdom.
  • Clinical Sciences Department, hVIVO Services Limited, London, England, United Kingdom.
  • hSite Medical Operations, hVIVO Services Limited, London, England, United Kingdom.

ORCID-Profile: Takamichi Baba, Nao Kawaguchi, Atsuko Yamamoto, Alex Mann, Takeki Uehara

Förderung

  • Shionogi & Co., Ltd

Zitieren

APA

Byrne, S., Baba, T., Kawaguchi, N., Yamamoto, A., Nakano, Y., Dorrepaal, C., Londt, B., Mann, A., Veselinski, N., & Uehara, T. (2026). Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag367

Vancouver

Byrne S, Baba T, Kawaguchi N, Yamamoto A, Nakano Y, Dorrepaal C, et al. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag367

BibTeX
@article{Byrne2026,
  author = {Byrne, Stuart and Baba, Takamichi and Kawaguchi, Nao and Yamamoto, Atsuko and Nakano, Yoshiyuki and Dorrepaal, Caroline and Londt, Brandon and Mann, Alex and Veselinski, Nikolay and Uehara, Takeki},
  title = {Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the Respiratory Syncytial Virus L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag367}
}
Kostenlos starten →